COVID-19 Vaccines and Treatment: The Race for Global Equity
Our team aggregates and analyzes publicly available data to track the purchases, manufacturing, and donations of COVID-19 vaccines and therapeutics. The data are provided in interactive visuals on this site, as well as in a downloadable spreadsheet (updated regularly), to strengthen data-driven understandings of the global equity challenges and potential solutions in pandemic response. Please contact us at firstname.lastname@example.org with any additions or corrections to the data presented here.
Over the past few months, the number of changes to the COVID-19 vaccine purchase and manufacturing data have slowed down significantly. Relative to what we saw in 2020 and 2021, there are now very few new purchases. At the same time, we are starting to see manufacturing contract, rather than expand. Given these changes, we have decided to stop new data updates for the vaccine purchases and manufacturing data with the last update dated June 9, 2022. The latest data update available on the website includes vaccine purchases and manufacturing data for the last time. If we see significant changes in either of these areas over time, we will updated our data and notify our partners.
Our team is assessing the vaccine donations landscape and will make a decision shortly about whether and how to continue updating this data. In the meantime, we are reviewing our existing donations data and cross-checking against additional sources. We will release a full vaccine donations data update when that process is complete, which we anticipate will be July 1.
We continue to collect and report of COVID-19 therapeutics data weekly. The latest data can be downloaded here: https://launchandscalefaster.org/COVID-19.
As always, please let us know if you have any questions or spot any gaps or discrepancies in the data. And if you have found the data useful, we would love to hear how you have used it.
For further questions, to be added our Speedometer Updates listserv, or other media requests, please email Jessica Harris, email@example.com.
Latest COVID-19 Vaccine and Therapeutics Data
Download our latest vaccine donations data update from May 5, 2023 (.xlsx).
Download our latest therapeutics data update from May 5, 2023 (.xlsx).
Archived vaccine data (downloads available).
Read the Framework for a Global Action Plan for COVID-19 Response released Tuesday, August 24, 2021
We are at an exceedingly perilous and urgent moment in the COVID-19 pandemic. As the Delta variant has demonstrated, we are fighting a virus that doesn’t respect borders and rapidly advances across continents. If the virus continues to circulate unchecked in large parts of the world, we will see not only many more millions of infections and deaths, but also new variants that could totally pierce vaccine immunity, returning the world to square one.
Read our August 2, 2021 Open Letter to the Biden-Harris Administration: US Emergency Plan for Global COVD-19 Relief
We are at an exceedingly perilous and urgent moment in the COVID-19 pandemic. The Delta variant, vastly more dangerous and pernicious than the original SARS-CoV-2 virus, has rapidly spread worldwide. It has been driving a deadly summer surge in the US; ripping through Latin America; causing Indonesia to become the next Asian hotspot; and fueling a third wave of the pandemic in Africa, where less than two percent of the population has been fully vaccinated. To respond, the US must build on the rapid development and availability of its highly effective vaccines – ensuring easy access for any American who wants to be vaccinated, and readiness to rapidly deploy boosters and vaccines for children. But as Delta has shown, an effective domestic response is not enough. Read more here.
Read The Hill's July 8, 2021article: Beyond ample supply, hurdles abound in the race to vaccinate the globe
Read our June 7, 2021 Open Letter to the G7: U.S. Global Health Experts Urge G7 Action to Vaccinate the World Quickly and Equitably
Read our May 17, 2021 Open Letter to the Biden Administration and US Congress Calling for Urgent High-Level US Leadership to Address Escalating Global COVID-19 Vaccine Crisis
Read our May 1, 2021 Op-Ed in the MIT Technology Review: What India needs to get through its covid crisis
Read our April 28, 2021 Op-Ed from The Hill: Poorer nations face tougher choice about vaccines
Read our April 28, 2021 Op-Ed from Politico: Why America’s Next Covid Push Should Be Outside America
Read our April 15, 2021 paper on Reducing Global COVID Vaccine Shortages: New Research and Recommendations for US Leadership
Read our March 19, 2021 Issue Brief: Deciphering the Manufacturing Landscape for COVID-19 Vaccines.
Read our November 2, 2020 Press Release on COVID-10 Vaccine Advance Market Commitments.
Our research has recently been featured in The New York Times, The Washington Post, The Economist, Bloomberg, and The Guardian and many other outlets, including El Diario in Spain, as well as Al Jazeera. View and listen to these brief commentaries from our research team on BBC, NPR, NYPoficial (Paraguay) and ABC News.
Featuring Dr. Krishna Udayakumar, Director, Duke GHIC - VOX, April 28, 2021
Dr. Ernesto Ortiz, Senior Manager - CNN Espanol, February 22, 2021
For Media Requests please email Jessica Harris at firstname.lastname@example.org or call + 1 919 668 7923.
These data and analyses are updated every week. We are tracking the data to the best of our ability, though there may be gaps given the speed of developments and lack of detailed information in many public statements.
Suggested citation: Duke Global Health Innovation Center. (2021). Launch and Scale Speedometer. Duke University. Retrieved from: https://launchandscalefaster.org/covid-19
Except where otherwise noted, this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.